abstract: UNASSIGNED: Previous studies have demonstrated that microRNA (miRNA) are essential in @entity2 development and invasion. The close association between @entity7 ( @entity7 ) and @entity3 ( @entity3 ) has been previously reported. miRNA  -7  ( @entity8 ) inhibits the translation of @entity7 protein. Therefore, the present study aimed to assess the underlying molecular mechanism of @entity8 in @entity0 @entity3 cell lines, to provide a novel therapeutic biomarker of @entity3 in the future. The present study detected the expression of @entity8  in  60  @entity3 tissues by reverse transcription  -quantitative polymerase chain reaction (RT  -qPCR). The association between the expression of @entity8 and clinical pathological factors was analyzed. Overexpression/underexpression of @entity8  were established by transfecting miR  -7mimics/inhibitors into HCT  -8 and Caco  -2  cells. The transfected @entity3 cell lines were used in cell viability and scratching assays. The regulation of @entity7 by @entity8 was analyzed by western blotting and RT  -qPCR. It was demonstrated that the expression of @entity8 negatively correlated with @entity6 and @entity2 node @entity1 staging in @entity3 (P<0.05). Inhibition of @entity8 led to an accelerated ability of proliferation and migration in @entity3 cell lines. Additionally, overexpression of @entity8 inhibited the proliferation and migration of @entity3 cells. In addition, it was also observed that @entity8 regulated the proliferation and migration of @entity3 by regulating the protein expression of @entity7 , therefore, regulating the expression of @entity4 and @entity5 . @entity8 inhibited the proliferation and migration of @entity3 cells by regulating @entity7 . These findings suggested that @entity8 may be a novel therapeutic target for @entity3 .

title: MicroRNA  -7 suppresses @entity0 XXXX invasion and proliferation by targeting the expression of @entity7 .

answer: @entity3


abstract: UNASSIGNED: Previous studies have demonstrated that microRNA (miRNA) are essential in @entity2 development and invasion. The close association between @entity7 ( @entity7 ) and @entity3 ( @entity3 ) has been previously reported. miRNA  -7  ( @entity8 ) inhibits the translation of @entity7 protein. Therefore, the present study aimed to assess the underlying molecular mechanism of @entity8 in @entity0 @entity3 cell lines, to provide a novel therapeutic biomarker of @entity3 in the future. The present study detected the expression of @entity8  in  60  @entity3 tissues by reverse transcription  -quantitative polymerase chain reaction (RT  -qPCR). The association between the expression of @entity8 and clinical pathological factors was analyzed. Overexpression/underexpression of @entity8  were established by transfecting miR  -7mimics/inhibitors into HCT  -8 and Caco  -2  cells. The transfected @entity3 cell lines were used in cell viability and scratching assays. The regulation of @entity7 by @entity8 was analyzed by western blotting and RT  -qPCR. It was demonstrated that the expression of @entity8 negatively correlated with @entity6 and @entity2 node @entity1 staging in @entity3 (P<0.05). Inhibition of @entity8 led to an accelerated ability of proliferation and migration in @entity3 cell lines. Additionally, overexpression of @entity8 inhibited the proliferation and migration of @entity3 cells. In addition, it was also observed that @entity8 regulated the proliferation and migration of @entity3 by regulating the protein expression of @entity7 , therefore, regulating the expression of @entity4 and @entity5 . @entity8 inhibited the proliferation and migration of @entity3 cells by regulating @entity7 . These findings suggested that @entity8 may be a novel therapeutic target for @entity3 .

title: MicroRNA  -7 suppresses XXXX @entity3 invasion and proliferation by targeting the expression of @entity7 .

answer: @entity0


abstract: PURPOSE: We compared the efficiency, side effects and effects on spermatogenesis of sclerotherapy with @entity3 and surgical treatment for hydrocele. MATERIALS AND METHODS: A total of 67 @entity0 (80 hydroceles) were randomly divided into 2 groups of 40 hydroceles each. One group underwent @entity3 sclerotherapy and the other underwent hydrocelectomy. Spermiograms were done before, 6 and 12 months after treatment in @entity0 able to ejaculate. RESULTS: In the sclerotherapy group 47.5%, 30%, 12.5%, 5% and 2.5% of the hydroceles were cured with 1 to 5 injections, respectively, but 2.5% were not cured even with 6 injections. There were no complaints of @entity1 or @entity2 in these cases. All @entity0 returned to normal activity on the same day. In the hydrocelectomy group 97.5% and 2.5% of hydroceles were cured with 1 and 2 operations, respectively. There was @entity1 postoperatively in 73.5% of the @entity0 and @entity2 in 5%, while 62.5% required an average of 4.5 days of rest and were absent from work for 10 days. There was no significant statistical alteration in spermatozoid concentration in the preoperative, and 6 and 12-month postoperative counts in the groups (p = 0.385). CONCLUSIONS: Sclerotherapy for hydrocele with @entity3 is as efficacious as hydrocelectomy, while causing less morbidity and similar effects on spermatogenesis.

title: Comparative study of sclerotherapy with XXXX and surgical treatment for hydrocele.

answer: @entity3


abstract: PURPOSE: The use of continent urinary reservoirs has gained wide acceptance, particularly in urinary reconstruction in @entity0 with a small capacity or @entity2 . When augmentation cystoplasty is combined with clean intermittent catheterization, @entity0 are often able to achieve continence with low intravesical filling pressures and renal preservation. Often this approach requires fashioning a continent cutaneous stoma, which remains the most challenging aspect of continent urinary reservoirs. We analyzed our experience with continent diversion in @entity0 with exstrophy- @entity5 to determine complications and long-term results. MATERIALS AND METHODS: We performed a retrospective database review of 704 cases of exstrophy- @entity5 . Medical records were then used to identify those @entity0 who had undergone creation of a continent urinary reservoir. Charts were reviewed to determine initial diagnosis, augmentation technique, continence mechanism, age, preoperative and postoperative bladder capacity, continence status and complications. RESULTS: Of the 91 @entity0 identified (68 male, 23 female) who had undergone continent urinary diversion classic @entity1 was present in 80, @entity6 in 8, complete @entity4 in 2 and @entity5 in 1. The most common techniques for augmentation and continent diversion were ileocystoplasty (41 @entity0 [45%]) and sigmoid cystoplasty (30 [33%]), respectively. Appendix was used in 67 @entity0 (74%) and variants of the Mitrofanoff procedure using segments of tapered ileum or ureter were used to create a continent stoma in 10 (11%). Bladder neck transection was performed in 59 @entity0 (65%). Mean age at augmentation and continent diversion was 8 years (range 2 to 25), with a mean preoperative bladder capacity of 77 cc (15 to 220). Mean followup was 6 years (range 6 months to 12 years). Of the 91 @entity0 85 (93%) were continent with clean intermittent catheterization per stoma. Of these 85 @entity0 13 required anticholinergics and alpha-agonists to achieve continence. Six @entity0 (7%) were incontinent after the procedure. Analysis of bladder capacity measurements after augmentation and continent diversion revealed that mean postoperative volume and mean volume increase were 404 cc (range 250 to 640) and 524%, respectively. The most common complications were @entity3 formation (24 @entity0 [26%]) and stomal stenosis (21 [23%]). @entity3 recurred in 9 @entity0 and stomal stenosis in 3. Other less common complications were vesicourethral fistula (3 @entity0 ) and a small bladder perforation (2). CONCLUSION: Augmentation and continent diversion procedures can increase the functional capacity of the small contracted noncompliant exstrophic bladder, and allow the vast majority of @entity0 to achieve continence and preserve renal function. @entity3 and stomal stenosis pose the most significant long-term complications in these @entity0 .

title: Continent urinary diversion and the exstrophy- XXXX complex.

answer: @entity5


abstract: UNASSIGNED: The Hereditary Spastic Paraparesis (HSP) or @entity7 is a heterogeneous @entity1 of the spinal cord. It is genetically transmitted and characterized by a progressive @entity2 , @entity3 of the lower limbs and @entity5 . There is no specific pharmacological treatment. The pharmacological therapy decreases the muscle tone and prevents stiffening). Physiotherapy restrains the progression of @entity6 , delays contraction of the tendons and gives greater mobility to @entity0 affected by the disease. The aim of this study is to demonstrate the efficacy of the combined treatment Fkt and Btx-A in @entity0 with HSP. Retrospective study was conducted recruiting ten @entity0 with @entity3 according to Asworth modified scale of at least 2 and with gait deficit. They received treatment for 5 years with incobotulinumtoxinA and physiokinesiotherapy for addressing @entity3 in the lower limbs. We evaluated muscle tone with miometric measurement both at the first visit (T0), and at subsequent ones (T1 after 30 days, T2 after 3 months from the first infiltration, T3 after 4 months up to the date of the following infiltration, T4 after 5 months). Baropodometric examination has proven essential for the study of the distribution of loads in statics and dynamics. The data analysis regarding tone assessment through measurements with Myoton highlighted hypertonus reduction in all the three muscle groups examined at T1 and the maintenance of constant values up to 5 months after the first infiltration. It also showed an increase in the percentage of back foot loading in both feet up to T4 (new inoculation, p<0, 05%). Baropodometric examination in dynamics (in particular the speed of the step) showed a gradual increase in this parameter which reaches a peak at 5 months (p<0, 05%) and then declines again in conjunction with the next infiltration treatment. This study showed the benefit of combined treatment with Btx and Fkt. The use of a local muscle relaxant drug with a physical targeted exercise guarantees better mobility of the treated segments, reducing tendon retractions as much as possible, and guarantees an adequate postural alignment. Baropodometric examination highlights a more advantageous distribution load, quite essential for avoiding @entity4 due to overload. Our data observation in the 5 years study shows how the curve relative to the speed of step and the graphics related to the variations of muscle tone remain almost constant with detectable improvement.

title: Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in @entity0 with XXXX .

answer: @entity7


abstract: UNASSIGNED: The Hereditary Spastic Paraparesis (HSP) or @entity7 is a heterogeneous @entity1 of the spinal cord. It is genetically transmitted and characterized by a progressive @entity2 , @entity3 of the lower limbs and @entity5 . There is no specific pharmacological treatment. The pharmacological therapy decreases the muscle tone and prevents stiffening). Physiotherapy restrains the progression of @entity6 , delays contraction of the tendons and gives greater mobility to @entity0 affected by the disease. The aim of this study is to demonstrate the efficacy of the combined treatment Fkt and Btx-A in @entity0 with HSP. Retrospective study was conducted recruiting ten @entity0 with @entity3 according to Asworth modified scale of at least 2 and with gait deficit. They received treatment for 5 years with incobotulinumtoxinA and physiokinesiotherapy for addressing @entity3 in the lower limbs. We evaluated muscle tone with miometric measurement both at the first visit (T0), and at subsequent ones (T1 after 30 days, T2 after 3 months from the first infiltration, T3 after 4 months up to the date of the following infiltration, T4 after 5 months). Baropodometric examination has proven essential for the study of the distribution of loads in statics and dynamics. The data analysis regarding tone assessment through measurements with Myoton highlighted hypertonus reduction in all the three muscle groups examined at T1 and the maintenance of constant values up to 5 months after the first infiltration. It also showed an increase in the percentage of back foot loading in both feet up to T4 (new inoculation, p<0, 05%). Baropodometric examination in dynamics (in particular the speed of the step) showed a gradual increase in this parameter which reaches a peak at 5 months (p<0, 05%) and then declines again in conjunction with the next infiltration treatment. This study showed the benefit of combined treatment with Btx and Fkt. The use of a local muscle relaxant drug with a physical targeted exercise guarantees better mobility of the treated segments, reducing tendon retractions as much as possible, and guarantees an adequate postural alignment. Baropodometric examination highlights a more advantageous distribution load, quite essential for avoiding @entity4 due to overload. Our data observation in the 5 years study shows how the curve relative to the speed of step and the graphics related to the variations of muscle tone remain almost constant with detectable improvement.

title: Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in XXXX with @entity7 .

answer: @entity0


abstract: The purpose of this study was to characterize quantitative computed tomography (QCT) in our multi-detector computed tomography (MDCT) scanner with regard to the influence of the QCT phantom on dose and the influence of varying mA and CIRS phantom size on bone mineral density (BMD) measurements. We accomplish this by scanning a commercially available QCT phantom and a corresponding quality assurance phantom. To assess the feasibility of having the QCT phantom in place while @entity0 are being scanned, we measured radiation dose difference in a CT body phantom with and without the QCT phantom on the CT table and also, with and without the use of dose modulation programs. We also analyzed reconstructed QCT phantom images with the manufacturer's software to measure BMD. Although @entity0 characteristics may be different, leading to different mA values, the influence of the QCT phantom on the dose to @entity0 was minimal when compared with doses measured without the phantom in place. Average BMD measurements were not significantly affected by varying mA, for a fixed-size phantom. The average BMD exhibited a weak dependence on computerized imaging reference systems (CIRS) torso phantom size, with a propensity for decreasing BMD with increasing size. Measurement precision was unaffected by varying CIRS size. Having the ability to measure bone density as part of the routine management of @entity1 @entity0 , with no added cost, time, or radiation dose, will allow for the prospective evaluation of bone mineral changes. We believe that this ability will facilitate the detection of abnormal @entity2 and will lead to better management of this loss and, thus, reduce the complications and associated morbidity in these @entity1 survivors.

title: Assessing the clinical utility of quantitative computed tomography with a routinely used diagnostic computed tomography scanner in a XXXX center.

answer: @entity1


abstract: PURPOSE: Isolated accounts of neoplastic pouch transformation suggest the need to perform routine ileoanal pouch surveillance with biopsy. These reports imply a model of @entity5 to @entity1 . More recent reports studying "high risk" @entity3 @entity0 concluded that the development of @entity8 is indeed a rare event. This study was designed to evaluate our institutional incidence of @entity5 in ileoanal pouch during long-term follow-up. METHODS: A prospective database of all @entity0 undergoing ileoanal pouch construction (n = 767) was queried for all @entity0 undergoing pouch biopsy between 1983 and 2001. All @entity0 with @entity3 who underwent pouch biopsy were included. This excluded @entity0 with @entity2 , indeterminate @entity7 , and @entity6 . Pathology reports were reviewed for histologic evidence of @entity4 , atypia, @entity9 , @entity5 , or @entity1 . @entity0 age at biopsy, pouch age at time of biopsy, and pathology were analyzed. RESULTS: The @entity8 of 160 @entity0 were surveyed with biopsies a total of 222 times. The average length of follow-up from pouch construction to time of surveillance and biopsy was 8.4 +/- 4.6 years. There were 83 @entity0 (52 percent) whose pouches were older than 10 years (mean, 12.7 +/- 2) at time of surveillance. With over 1,800 pouch-years of surveillance, only 1 @entity0 had focal, low-grade @entity5 in the pouch. This @entity0 demonstrated no evidence of @entity5 on further surveillance. CONCLUSION: Even with long-term follow-up of ileoanal pouch @entity0 , there is little evidence to support routine biopsy of the ileal mucosa in @entity3 @entity0 .

title: Is routine pouch surveillance for @entity5 indicated for XXXX ?

answer: @entity8


abstract: PURPOSE: Isolated accounts of neoplastic pouch transformation suggest the need to perform routine ileoanal pouch surveillance with biopsy. These reports imply a model of @entity5 to @entity1 . More recent reports studying "high risk" @entity3 @entity0 concluded that the development of @entity8 is indeed a rare event. This study was designed to evaluate our institutional incidence of @entity5 in ileoanal pouch during long-term follow-up. METHODS: A prospective database of all @entity0 undergoing ileoanal pouch construction (n = 767) was queried for all @entity0 undergoing pouch biopsy between 1983 and 2001. All @entity0 with @entity3 who underwent pouch biopsy were included. This excluded @entity0 with @entity2 , indeterminate @entity7 , and @entity6 . Pathology reports were reviewed for histologic evidence of @entity4 , atypia, @entity9 , @entity5 , or @entity1 . @entity0 age at biopsy, pouch age at time of biopsy, and pathology were analyzed. RESULTS: The @entity8 of 160 @entity0 were surveyed with biopsies a total of 222 times. The average length of follow-up from pouch construction to time of surveillance and biopsy was 8.4 +/- 4.6 years. There were 83 @entity0 (52 percent) whose pouches were older than 10 years (mean, 12.7 +/- 2) at time of surveillance. With over 1,800 pouch-years of surveillance, only 1 @entity0 had focal, low-grade @entity5 in the pouch. This @entity0 demonstrated no evidence of @entity5 on further surveillance. CONCLUSION: Even with long-term follow-up of ileoanal pouch @entity0 , there is little evidence to support routine biopsy of the ileal mucosa in @entity3 @entity0 .

title: Is routine pouch surveillance for XXXX indicated for @entity8 ?

answer: @entity5


abstract: For @entity1 ,intraoperative radiation therapy (IORT) administered to the site with the highest locoregional recurrence risk carries the rationale to improve @entity1 control. An IORT effect on survival remains unclear. IORT impact on postoperative outcomes after pancreatectomy for @entity2 was analyzed, with a specific attempt to correct for the nonrandom IORT treatment assignment, and to account for treatment group imbalances in the interpretation of outcome differences. A propensity-score-adjusted analysis, based on variable selection by logistic regression, was used to rebalance treatments. Between 1989 and 1999, 61 @entity0 underwent partial or total pancreatectomy for a primary @entity2 at the City of Hope National Medical Center. Diagnoses included pancreatic (n = 36), duodenal (n = 11), ampullary (n = 10), and @entity3 (n = 4). Thirty @entity0 received IORT to the resection area, with a median dose of 15 Gy (range: 10-20), followed by postoperative external beam radiation (n = 24). Mortality was 0%, the complication rate 61%. Of 33 @entity0 with a documented recurrence, 6 had an isolated locoregional recurrence only (1 IORT versus 5 no IORT, = 0.05); the systemic recurrence pattern differed as well (IORT 94%, no IORT 67%; = 0.04). IORT had no significant impact on hospital stay (overall median: 17 days), disease-free survival (16 months), and overall survival (23 months) when adjusted for those most relevant variables reflecting IORT treatment group assignment propensity. After adjustment for relevant propensity factors, IORT was not linked to a significantly increased risk for complications, hospital stay, or survival hazard. The recurrence pattern may be affected in some @entity0 , but systemic recurrences predominate. We continue to explore IORT in combination with systemic chemotherapy.

title: Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for XXXX : a propensity score analysis.

answer: @entity2


abstract: OBJECTIVE: @entity1 can be treated with continuous renal replacement therapy (CRRT) or intermittent hemodialysis. There is no difference in mortality, although @entity0 treated with CRRT may have a higher rate of renal recovery. Given these considerations, an estimate of the costs by modality may help in choosing the method of dialysis. As such, the objective of this study was to estimate the cost of CRRT and intermittent hemodialysis in the intensive care unit and to explore the impact of renal recovery on subsequent clinical outcomes and costs among survivors. DESIGN: Retrospective cohort study of all @entity0 who developed @entity1 and required dialysis between April 1, 1996, and March 31, 1999. SETTING: Two tertiary care intensive care units in Calgary, Canada. @entity0 : A total of 261 critically ill @entity0 . INTERVENTIONS: None. MEASUREMENTS: All @entity0 were followed to determine in-hospital and subsequent clinical outcomes (survival and frequency of renal recovery). The immediate and potential long-term costs of CRRT and intermittent hemodialysis were measured. MAIN RESULTS: The cost of performing CRRT ranged from Can 3,486 dollars to Can 5,117 dollars per week, depending on the modality and the anticoagulant used, and it was significantly more expensive than intermittent hemodialysis (Can 1,342 dollars per week). Survivors with renal recovery spent significantly fewer days in hospital (11.3 vs. 22.5 days, p<.001) and incurred less healthcare costs (11,192 dollars vs. 73,273 dollars, p<.001) over the year after hospital discharge compared with survivors who remained on dialysis. CONCLUSIONS: Immediate cost savings could be achieved by increasing the use of intermittent hemodialysis rather than CRRT for @entity0 with @entity1 in the intensive care unit. Because of the high cost of ongoing dialysis, CRRT may still be an economically efficient treatment if it improves renal recovery among survivors; further study in this area is required.

title: Cost of XXXX requiring dialysis in the intensive care unit: clinical and resource implications of renal recovery.

answer: @entity1


abstract: Activation of the translation initiation factor 4E ( @entity7 ) promotes malignant transformation and @entity1 . Signaling through the AKT-mTOR pathway activates @entity7 by phosphorylating the inhibitory 4E binding proteins (4E-BP). This liberates @entity7 and allows binding to @entity8 . @entity7 can then be phosphorylated at @entity5 209 by the MAPK-interacting kinases (Mnk), which also interact with @entity8 . Although dispensable for normal development, Mnk function and @entity7 phosphorylation promote cellular proliferation and survival and are critical for malignant transformation. Accordingly, Mnk inhibition may serve as an attractive @entity2 therapy. We now report the identification of a potent, selective and orally bioavailable Mnk inhibitor that effectively blocks 4E phosphorylation both in vitro and in vivo. In cultured @entity2 cell lines, Mnk inhibitor treatment induces apoptosis and suppresses proliferation and soft agar colonization. Importantly, a single, orally administered dose of this Mnk inhibitor substantially suppresses @entity7 phosphorylation for at least 4 hours in @entity0 xenograft @entity2 tissue and @entity3 liver tissue. Moreover, oral dosing with the Mnk inhibitor significantly suppresses outgrowth of experimental B16 @entity4 pulmonary @entity1 as well as growth of subcutaneous HCT116 @entity6 xenograft @entity2 , without affecting body weight. These findings offer the first description of a novel, orally bioavailable MNK inhibitor and the first preclinical proof-of-concept that MNK inhibition may provide a tractable @entity2 therapeutic approach.

title: Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung XXXX .

answer: @entity1


abstract: OBJECTIVE: Heart rate recovery (HRR) is a recognised marker used in clinical practice for assessing the risk of @entity3 . Physical exercise leads to an improvement in HRR and has a proven beneficial effect on erection quality (EQ) related to the activity of the autonomic nervous system in @entity0 with @entity1 ( @entity1 ). This paper evaluates the relationship between HRR and EQ in @entity0 with @entity1 and @entity2 ( @entity2 ) who underwent cardiac rehabilitation. METHODS: The main analysis was based on the Mann-Whitney U test, Wilcoxon signed-rank test, Spearman correlation coefficient, Pearson's chi-square test, chi-square test, with the Yates correction and (if possible) parametric tests were used. This prospective, non-randomised intervention study included 124 @entity0 with @entity1 and @entity2 [International Index of Erectile Function (IIEF-5) scores of  <=21]. Of these, 89 @entity0 underwent a 6-month cardiac rehabilitation phase III programme, whereas 35 did not. The results of the @entity0 ' total IIEF-5 scores and their HRR, demographic and clinical data were analysed. RESULTS: The results of the 89 rehabilitated @entity0 (mean age: 60.44  9.29 years) and 35 controls (mean age: 61.43  8.81 years) were analysed. In the rehabilitated @entity0 , the mean baseline IIEF-5 score was 13.15  5.76 (95% CI: 11.93-14.36) and HRR was 16.49  7.68/min (95% CI: 14.88-18.11). After cardiac rehabilitation, the parameters of @entity2 and HRR improved significantly and were significantly higher than those of the controls; the mean IIEF-5 score of the rehabilitated group increased to 15.36  6.51 (95% CI: 13.99-16.73), while HRR increased to 21.40  7.25/min (95% CI: 19.88-22.93). A significant correlation was found between    HRR and    EQ (r=0.409791) as a result of the 6-month cardiac training programme. CONCLUSION: Cardiac rehabilitation assessed by HRR has a sizable effect on autonomic balance in @entity0 with @entity1 and @entity2 , which plays a significant role in the mechanism of erection improvement.

title: Heart rate recovery, cardiac rehabilitation and XXXX in males with @entity1 .

answer: @entity2


abstract: OBJECTIVE: Heart rate recovery (HRR) is a recognised marker used in clinical practice for assessing the risk of @entity3 . Physical exercise leads to an improvement in HRR and has a proven beneficial effect on erection quality (EQ) related to the activity of the autonomic nervous system in @entity0 with @entity1 ( @entity1 ). This paper evaluates the relationship between HRR and EQ in @entity0 with @entity1 and @entity2 ( @entity2 ) who underwent cardiac rehabilitation. METHODS: The main analysis was based on the Mann-Whitney U test, Wilcoxon signed-rank test, Spearman correlation coefficient, Pearson's chi-square test, chi-square test, with the Yates correction and (if possible) parametric tests were used. This prospective, non-randomised intervention study included 124 @entity0 with @entity1 and @entity2 [International Index of Erectile Function (IIEF-5) scores of  <=21]. Of these, 89 @entity0 underwent a 6-month cardiac rehabilitation phase III programme, whereas 35 did not. The results of the @entity0 ' total IIEF-5 scores and their HRR, demographic and clinical data were analysed. RESULTS: The results of the 89 rehabilitated @entity0 (mean age: 60.44  9.29 years) and 35 controls (mean age: 61.43  8.81 years) were analysed. In the rehabilitated @entity0 , the mean baseline IIEF-5 score was 13.15  5.76 (95% CI: 11.93-14.36) and HRR was 16.49  7.68/min (95% CI: 14.88-18.11). After cardiac rehabilitation, the parameters of @entity2 and HRR improved significantly and were significantly higher than those of the controls; the mean IIEF-5 score of the rehabilitated group increased to 15.36  6.51 (95% CI: 13.99-16.73), while HRR increased to 21.40  7.25/min (95% CI: 19.88-22.93). A significant correlation was found between    HRR and    EQ (r=0.409791) as a result of the 6-month cardiac training programme. CONCLUSION: Cardiac rehabilitation assessed by HRR has a sizable effect on autonomic balance in @entity0 with @entity1 and @entity2 , which plays a significant role in the mechanism of erection improvement.

title: Heart rate recovery, cardiac rehabilitation and @entity2 in males with XXXX .

answer: @entity1


abstract: @entity1 treatment is essential in @entity0 with @entity3 ( @entity3 ) to block platelet @entity8 ( @entity5 )    synthesis. @entity6 is known to enhance platelet reactivity induced by other agonists and to be elevated in @entity0 with @entity3 due to stress. Our objective was to study the influence of @entity6 on platelet @entity5    synthesis in @entity0 treated with @entity1 for @entity3 at early onset (within 48 hours) and the potential biochemical mechanisms involved in the functional response. Washed platelets from 45 @entity0 with @entity3 and 10 @entity1 -free controls were stimulated with @entity7 (AA) or AA + @entity6 , and aggregation and @entity5    synthesis were evaluated. Full platelet aggregation was recorded in 8/45 @entity0 (18%) with a partial @entity5    inhibition (86%) vs. the @entity1 -free controls. Platelets from the remaining 37 @entity0 did not aggregate to AA and had @entity5    inhibition >95%. However, when platelets were simultaneously stimulated with AA + @entity6 , in 25/37 @entity0 a large intensity of aggregation (73%) was observed and a 5.5-fold increase in @entity5    synthesis, although this remained residual (<5% of @entity1 -free controls). This residual- @entity5    was critical in the functional response, as demonstrated by the complete inhibition by @entity5    receptor blockade or additional @entity1 in vitro. The @entity10 -3-kinase activity and the cytosolic @entity2 levels participated in this platelet response elicited by a receptor cooperation mechanism, while the Rho/ @entity12 (ROCK) pathway or the blockade of the @entity4 receptors ( @entity11 , @entity9 ) were without effect. Residual-cyclooxygenase -1 activity and @entity6 enhance @entity5   -dependent platelet function, which may reduce the clinical benefit of @entity1 in @entity0 with @entity3 .

title: Residual cyclooxygenase-1 activity and @entity6 reduce the antiplatelet effect of @entity1 in XXXX with @entity3 .

answer: @entity0


abstract: @entity1 treatment is essential in @entity0 with @entity3 ( @entity3 ) to block platelet @entity8 ( @entity5 )    synthesis. @entity6 is known to enhance platelet reactivity induced by other agonists and to be elevated in @entity0 with @entity3 due to stress. Our objective was to study the influence of @entity6 on platelet @entity5    synthesis in @entity0 treated with @entity1 for @entity3 at early onset (within 48 hours) and the potential biochemical mechanisms involved in the functional response. Washed platelets from 45 @entity0 with @entity3 and 10 @entity1 -free controls were stimulated with @entity7 (AA) or AA + @entity6 , and aggregation and @entity5    synthesis were evaluated. Full platelet aggregation was recorded in 8/45 @entity0 (18%) with a partial @entity5    inhibition (86%) vs. the @entity1 -free controls. Platelets from the remaining 37 @entity0 did not aggregate to AA and had @entity5    inhibition >95%. However, when platelets were simultaneously stimulated with AA + @entity6 , in 25/37 @entity0 a large intensity of aggregation (73%) was observed and a 5.5-fold increase in @entity5    synthesis, although this remained residual (<5% of @entity1 -free controls). This residual- @entity5    was critical in the functional response, as demonstrated by the complete inhibition by @entity5    receptor blockade or additional @entity1 in vitro. The @entity10 -3-kinase activity and the cytosolic @entity2 levels participated in this platelet response elicited by a receptor cooperation mechanism, while the Rho/ @entity12 (ROCK) pathway or the blockade of the @entity4 receptors ( @entity11 , @entity9 ) were without effect. Residual-cyclooxygenase -1 activity and @entity6 enhance @entity5   -dependent platelet function, which may reduce the clinical benefit of @entity1 in @entity0 with @entity3 .

title: Residual cyclooxygenase-1 activity and @entity6 reduce the antiplatelet effect of XXXX in @entity0 with @entity3 .

answer: @entity1


abstract: @entity1 treatment is essential in @entity0 with @entity3 ( @entity3 ) to block platelet @entity8 ( @entity5 )    synthesis. @entity6 is known to enhance platelet reactivity induced by other agonists and to be elevated in @entity0 with @entity3 due to stress. Our objective was to study the influence of @entity6 on platelet @entity5    synthesis in @entity0 treated with @entity1 for @entity3 at early onset (within 48 hours) and the potential biochemical mechanisms involved in the functional response. Washed platelets from 45 @entity0 with @entity3 and 10 @entity1 -free controls were stimulated with @entity7 (AA) or AA + @entity6 , and aggregation and @entity5    synthesis were evaluated. Full platelet aggregation was recorded in 8/45 @entity0 (18%) with a partial @entity5    inhibition (86%) vs. the @entity1 -free controls. Platelets from the remaining 37 @entity0 did not aggregate to AA and had @entity5    inhibition >95%. However, when platelets were simultaneously stimulated with AA + @entity6 , in 25/37 @entity0 a large intensity of aggregation (73%) was observed and a 5.5-fold increase in @entity5    synthesis, although this remained residual (<5% of @entity1 -free controls). This residual- @entity5    was critical in the functional response, as demonstrated by the complete inhibition by @entity5    receptor blockade or additional @entity1 in vitro. The @entity10 -3-kinase activity and the cytosolic @entity2 levels participated in this platelet response elicited by a receptor cooperation mechanism, while the Rho/ @entity12 (ROCK) pathway or the blockade of the @entity4 receptors ( @entity11 , @entity9 ) were without effect. Residual-cyclooxygenase -1 activity and @entity6 enhance @entity5   -dependent platelet function, which may reduce the clinical benefit of @entity1 in @entity0 with @entity3 .

title: Residual cyclooxygenase-1 activity and XXXX reduce the antiplatelet effect of @entity1 in @entity0 with @entity3 .

answer: @entity6


abstract: @entity1 treatment is essential in @entity0 with @entity3 ( @entity3 ) to block platelet @entity8 ( @entity5 )    synthesis. @entity6 is known to enhance platelet reactivity induced by other agonists and to be elevated in @entity0 with @entity3 due to stress. Our objective was to study the influence of @entity6 on platelet @entity5    synthesis in @entity0 treated with @entity1 for @entity3 at early onset (within 48 hours) and the potential biochemical mechanisms involved in the functional response. Washed platelets from 45 @entity0 with @entity3 and 10 @entity1 -free controls were stimulated with @entity7 (AA) or AA + @entity6 , and aggregation and @entity5    synthesis were evaluated. Full platelet aggregation was recorded in 8/45 @entity0 (18%) with a partial @entity5    inhibition (86%) vs. the @entity1 -free controls. Platelets from the remaining 37 @entity0 did not aggregate to AA and had @entity5    inhibition >95%. However, when platelets were simultaneously stimulated with AA + @entity6 , in 25/37 @entity0 a large intensity of aggregation (73%) was observed and a 5.5-fold increase in @entity5    synthesis, although this remained residual (<5% of @entity1 -free controls). This residual- @entity5    was critical in the functional response, as demonstrated by the complete inhibition by @entity5    receptor blockade or additional @entity1 in vitro. The @entity10 -3-kinase activity and the cytosolic @entity2 levels participated in this platelet response elicited by a receptor cooperation mechanism, while the Rho/ @entity12 (ROCK) pathway or the blockade of the @entity4 receptors ( @entity11 , @entity9 ) were without effect. Residual-cyclooxygenase -1 activity and @entity6 enhance @entity5   -dependent platelet function, which may reduce the clinical benefit of @entity1 in @entity0 with @entity3 .

title: Residual cyclooxygenase-1 activity and @entity6 reduce the antiplatelet effect of @entity1 in @entity0 with XXXX .

answer: @entity3


abstract: BACKGROUND: @entity5 of the @entity6 ( @entity6 ) remain a challenging problem worldwide, especially in areas with limited technical background; @entity3 is still a subject of controversy. The aim of this study was to analyze the clinical and paraclinical data of @entity0 with @entity5 of @entity6 who had an appendectomy performed. METHODS: During a period of 4 years, all @entity0 presenting with a @entity5 of the @entity6 were selected for our study and underwent clinical assessment and systematic ultrasonography of the abdomen; these served as a basis of selecting candidates for appendectomy. The intraoperative findings, histology results, and outcome after appendectomy were analyzed. RESULTS: Three hundred nineteen @entity0 presented with @entity5 of the @entity6 of which 213 could be finally analyzed; their mean age was 15.3 years; 192 @entity0 were females. They had @entity4 for 2-8 years. Echography showed a heterogeneous lesion in the @entity6 in 87% of the cases. The operative findings displayed adhesions and other signs of @entity1 in 182 cases. Pathological analysis frequently revealed @entity2 and lymphoplasmocytic infiltration indicative of @entity1 . Eighty-seven percent of the @entity0 were cured by appendectomy. CONCLUSIONS: There is a chronic process involving the appendix that occurs in the @entity6 of @entity0 with @entity5 , typically the adolescent female. Appendectomy usually solves the problem. The criteria for selection of candidates still need to be identified, but in the absence of laparoscopic facilities, we recommend appendectomy when no other cause for the @entity4 has been identified.

title: Clinical, ultrasonographic, and pathologic characteristics of XXXX with chronic right-lower-quadrant abdominal pain that may benefit from appendectomy.

answer: @entity0


abstract: Oral dosing of @entity5 @entity0 on days 2-5 after birth with @entity1 but not @entity2 disrupts the development of the myometrium, resulting in adult uterine @entity4 . Using laser capture microdissection and RT-PCR we have investigated @entity6 ( @entity6 ) and cognate receptor expression in uterine cells of 6-day-old pups that may be important in early developmental changes that give rise to @entity4 . @entity6 down-regulation is known to occur during terminal myogenic differentiation. @entity6 was found exclusively in endometrial luminal epithelium of controls. It was up-regulated 18-fold in the luminal epithelium following dosing with @entity1 but not @entity2 . Western blotting for @entity6 protein in the whole uterus showed a 25-fold increase after @entity1 treatment. Expression of the low affinity p75 neutrophin receptor ( @entity7 ) was twofold higher in the myometrium compared with luminal epithelium or stroma. This was not altered following @entity1 treatment. There was no detectable expression of high affinity @entity3 kinase receptor ( @entity8 ( @entity7 )). This study shows luminal epithelial cells of the endometrium primarily form @entity6 . This suggests that @entity6 normally regulates the differentiation of the mesenchyme into uterine myocytes through paracrine mechanisms and that an early disturbance of this process plays a key role in the subsequent development of @entity4 .

title: Comparison of the effect of oestradiol, @entity1 and XXXX on nerve growth factor-alpha expression in specific neonatal @entity0 uterine cell types using laser capture microdissection.

answer: @entity2


abstract: Oral dosing of @entity5 @entity0 on days 2-5 after birth with @entity1 but not @entity2 disrupts the development of the myometrium, resulting in adult uterine @entity4 . Using laser capture microdissection and RT-PCR we have investigated @entity6 ( @entity6 ) and cognate receptor expression in uterine cells of 6-day-old pups that may be important in early developmental changes that give rise to @entity4 . @entity6 down-regulation is known to occur during terminal myogenic differentiation. @entity6 was found exclusively in endometrial luminal epithelium of controls. It was up-regulated 18-fold in the luminal epithelium following dosing with @entity1 but not @entity2 . Western blotting for @entity6 protein in the whole uterus showed a 25-fold increase after @entity1 treatment. Expression of the low affinity p75 neutrophin receptor ( @entity7 ) was twofold higher in the myometrium compared with luminal epithelium or stroma. This was not altered following @entity1 treatment. There was no detectable expression of high affinity @entity3 kinase receptor ( @entity8 ( @entity7 )). This study shows luminal epithelial cells of the endometrium primarily form @entity6 . This suggests that @entity6 normally regulates the differentiation of the mesenchyme into uterine myocytes through paracrine mechanisms and that an early disturbance of this process plays a key role in the subsequent development of @entity4 .

title: Comparison of the effect of oestradiol, XXXX and @entity2 on nerve growth factor-alpha expression in specific neonatal @entity0 uterine cell types using laser capture microdissection.

answer: @entity1


abstract: Oral dosing of @entity5 @entity0 on days 2-5 after birth with @entity1 but not @entity2 disrupts the development of the myometrium, resulting in adult uterine @entity4 . Using laser capture microdissection and RT-PCR we have investigated @entity6 ( @entity6 ) and cognate receptor expression in uterine cells of 6-day-old pups that may be important in early developmental changes that give rise to @entity4 . @entity6 down-regulation is known to occur during terminal myogenic differentiation. @entity6 was found exclusively in endometrial luminal epithelium of controls. It was up-regulated 18-fold in the luminal epithelium following dosing with @entity1 but not @entity2 . Western blotting for @entity6 protein in the whole uterus showed a 25-fold increase after @entity1 treatment. Expression of the low affinity p75 neutrophin receptor ( @entity7 ) was twofold higher in the myometrium compared with luminal epithelium or stroma. This was not altered following @entity1 treatment. There was no detectable expression of high affinity @entity3 kinase receptor ( @entity8 ( @entity7 )). This study shows luminal epithelial cells of the endometrium primarily form @entity6 . This suggests that @entity6 normally regulates the differentiation of the mesenchyme into uterine myocytes through paracrine mechanisms and that an early disturbance of this process plays a key role in the subsequent development of @entity4 .

title: Comparison of the effect of oestradiol, @entity1 and @entity2 on nerve growth factor-alpha expression in specific neonatal XXXX uterine cell types using laser capture microdissection.

answer: @entity0


abstract: OBJECTIVE: Determine the efficacy and side effects of low-frequency repetitive transcranial magnetic stimulation (rTMS) to treat refractory neocortical @entity1 and study differences in effect between a figure-8 and round coil type. METHODS: This single-center randomized sham-controlled crossover trial (NCT01745952 on ClinicalTrials.gov) included 11 @entity0 with well-defined @entity3 . rTMS (0.5 Hz) was targeted to the focus during three treatment conditions consisting of 1,500  stimulations/day for 10  weekdays at 90% of resting motor threshold (rMT) followed by a 10-week observation period. @entity0 were randomized for the order in which the figure-8, round, and sham coil were used. Outcome assessors and @entity0 were blinded to the type of coil used. The primary outcome measure was the percentage of @entity2 reduction after active rTMS treatment. Other outcome measures were responder rate, quality of life, and side effects. RESULTS: There was no difference between a figure-8 and round coil. None of the @entity0 achieved an overall 50% @entity2 reduction. One @entity0 responded during 1  month after treatment with either active coil, followed by a significant increase in @entity2 frequency. Another @entity0 had a fourfold increase in @entity2 frequency during rTMS treatment. SIGNIFICANCE: This study provides evidence that rTMS is on average not effective for reducing @entity2 frequency. No difference in effectiveness between the different coil types was observed. It can, however, exacerbate @entity2 during treatment and lead to a rebound in @entity2 frequency after an initial reduction.

title: Randomized crossover sham-controlled clinical trial of targeted low-frequency transcranial magnetic stimulation comparing a figure-8 and a round coil to treat refractory neocortical XXXX .

answer: @entity1


abstract: Since February 2003, we have conducted surgical treatment on 8 @entity0 complicated with chronic @entity5 during cardiac surgery. A radial procedure was conducted on 7 @entity0 , and @entity2 was conducted on 1 @entity0 . Underlying diseases included @entity1 ( @entity1 ) in 5 @entity0 , @entity6 ( @entity6 ) in 1 @entity0 , @entity3 ( @entity3 ) + @entity6 in 1 @entity0 and chronic type A dissociation in 1 @entity0 . Simultaneous procedures included @entity1 ( @entity1 ) in 3 @entity0 , mitral valve replacement (MVR) in 3 @entity0 , @entity4 ( @entity4 ) + MVR in 1 @entity0 , and aortic root reconstruction by reimplantation procedure + total arch replacement in 1 @entity0 . The operation time was 320 to 840 minutes and 458.1   171.1 minutes on average. The cardiopulmonary bypass time was 204 to 404 minutes and 266.7    62.7 minutes on average. The aortic cross-clamp time was 142 to 271 minutes and 171   41.5 minutes on average. One @entity0 died in hospital. Six @entity0 returned to sinus rhythm, and 1 @entity0 required pacemaker implantation. The follow-up period was 2 to 37 months and 13.6    15 months on average. When cryoablation was changed to radiofrequency ablation to assist preparation of the block line, a tendency toward shortening of the aortic clamping time was observed.

title: Surgical treatment of chronic XXXX : Report of 8 cases.

answer: @entity5


abstract: @entity7 ( @entity7 ), a disorder caused almost exclusively by mutations in the X-linked gene, @entity8 , has a phenotype thought to be primarily of neurological origin. Disruption of @entity8 in @entity0 results in a prominent @entity7 -like phenotype. One of the consequences of @entity8 absence in the brain is altered functional and structural plasticity. We aimed to characterize synaptic effects related to plasticity in the hippocampus further and establish whether @entity3 are amenable to pharmacological reversal. Using male @entity0 in which @entity8 expression was prevented by a stop cassette, we assessed synaptic plasticity in area @entity6 at different phenotypic stages, scoring the @entity0 weekly for overt @entity7 -like signs. Strongly symptomatic @entity8 (stop/y) @entity0 displayed reduced long-term potentiation (LTP, 40.2  1.6% of wild-type), post-tetanic potentiation (PTP, 45  18.8% of wild-type) and paired-pulse facilitation ( @entity4 , 78  0.1% of wild type) (all P<0.05), the impairment increasing with symptom severity score. These @entity1 were absent in presymptomatic @entity0 . Repeated high frequency stimulation revealed pronounced LTP saturation in symptomatic @entity8 (stop/y) @entity0 , suggesting an LTP 'ceiling' effect. Bath application of the weak @entity2 receptor blocker @entity5 (1  M) resulted in partial restoration of a short-term plasticity component. These data support that idea that progressive functional synaptic impairment is a key feature in the @entity7 brain and demonstrate the potential for the pharmacological restoration of plasticity function.

title: Synaptic plasticity deficits in an experimental model of XXXX : long-term potentiation saturation and its pharmacological reversal.

answer: @entity7


abstract: A transient and reversible @entity4 state (LCOS) often occurs following surgery for @entity3 . Inappropriately managed LCOS is a risk factor for increased morbidity and @entity2 . LCOS may occasionally be progressive and refractory needing a period of "myocardial rest" with extracorporeal life support (ECLS). ECLS is currently considered a routine tool available for rapid deployment in most industrialized countries. Accumulated experience and refinements in technology have led to improving survivals - discharge survivals of 35%-50%, with almost 100% survival in select groups on elective left ventricular assist device. Thus, there is an increasing trend to initiate ECLS "early or electively in the operating room" in high-risk @entity0 . India has a huge potential need for ECLS given the large number of @entity0 presenting late with preexisting @entity1 or in circulatory collapse. ECLS is an expensive and resource consuming treatment modality and is not a viable therapeutic option in our country. The purpose of this paper is to reiterate an anticipatory, proactive approach to LCOS: (1) methods for early detection of evolving LCOS and (2) timely initiation of individualized therapy. This paper also explores what is feasible with the refinement of "simple, conventional, inexpensive strategies" for the management of LCOS. Therapy for LCOS should be multimodal based on the type of circulation and physiology. Our approach to LCOS includes: (1) intraoperative strategies, (2) aggressive afterload reduction, (3) lusitropy, (4) exclusion of structural defects, (5) harnessing cardiopulmonary interactions, and (6) addressing metabolic and endocrine abnormalities. We have achieved a discharge survival rate of greater than 97% with these simple methods.

title: Management of perioperative XXXX state without extracorporeal life support: What is feasible?

answer: @entity4


abstract: BACKGROUND CONTEXT: Compared with conventional microsurgical technique, the full endoscopic (FE) interlaminar approach is a more minimally invasive technique for the surgical treatment of @entity4 herniations. Its efficacy and safety have been confirmed by numerous studies. However, a steep learning curve with the use of such a complex technique is a major concern for the initial adoption of this technique. PURPOSE: To evaluate the learning curve of using an FE interlaminar technique for the surgical treatment of @entity3 . STUDY DESIGN: A prospective study of @entity0 with @entity3 who underwent discectomy via interlaminar approach assisted by FE instruments. @entity0 SAMPLE: Thirty @entity0 with @entity3 underwent discectomy using an interlaminar endoscopic-only approach between 2008 and 2009. METHODS: The @entity0 were divided into three groups of 10 sequential cases each. Group A consisted of the first 10 cases, Group B the subsequent 10 cases, and Group C the last 10 cases. The clinical evaluation data included operative time, length of hospital stay, visual analog scale (VAS) leg and back @entity2 scores, complications, and rate of conversion to an open. RESULTS: All @entity0 were observed prospectively for 1.61    0.22 years (range, 1.2-2.0 years). There was no measurable intraoperative bleeding and @entity1 in the three groups. Compared with Group A, the operative time in Group B was significantly decreased (p < .001). The @entity0 in Group C had much less operative time than in Group B (p = .002). There was no significant difference with length of hospital stay in the three groups (p = .897). The improvement of VAS leg and back @entity2 scores in each group was similar: there was a significant improvement (p < .01) at 3 months after surgery when compared with preoperative scores, but there was no statistical difference (p > .05) in the VAS leg and back @entity2 scores between 3 months after surgery and final follow-up. The complication rate was 12.5% for Group A, 10% for Group B, and 0% for Group C. The need for conversion to an open procedure for Group A was 20% compared with zero cases in both Groups B and C. There were no symptomatic recurrences in our study. CONCLUSIONS: Excellent clinical and minimally invasive outcomes can be obtained in the surgical treatment of @entity3 via the interlaminar approach assisted by FE technique. However, attention must be paid to the steep learning curve by using this complex technique. Imprecise anatomic orientation and manipulation inside the spinal canal are key factors in the steep learning curve. Obtaining microsurgical experience, attending workshops, and suitable @entity0 selection can help shorten the learning curve and decrease the complications.

title: An evaluation of the learning curve for a complex surgical technique: the full endoscopic interlaminar approach for XXXX herniations.

answer: @entity4


abstract: BACKGROUND:     To correlate cerebral perfusion and flow patterns after @entity2 revascularization within the circle of Willis ( @entity1 ). METHODS:     Sixty-five @entity0 (male/female ratio: 38/27; mean age: 63.2  8.4years; range: 44-82years) with symptomatic @entity2 stenosis underwent magnetic resonance (MR) angiography and perfusion imaging prior to and after @entity2 stenting (CAS). Regions of interest (ROIs) on the MR perfusion maps included the corona radiata (CR), centrum semiovale (CSO), occipital region (O), and basal ganglia region (BA) in both stented and non-stented hemispheres. The non-stented hemisphere was used as internal control. RESULTS:     Subjects were assigned to the altered @entity1 group (N=31) vs. the static @entity1 group (N=34). Thirty-one subjects (47.6%) had an altered flow pattern in the @entity1 after CAS, and thirty-four (52.4%) retained a static @entity1 configuration. Relative cerebral blood volume (rCBV) interhemispheric index correlated with @entity1 morphologic alterations after carotid stenting. Altered @entity1 group had a higher regional interhemispheric index of rCBV in the CR (1.23  0.15 vs. 0.87  0.13; P=0.03) and basal ganglia (1.25  0.12 vs. 0.91  0.11; P=0.03) compared to the static group. CONCLUSIONS:     An association between the regional cerebral blood volume (rCBV) interhemispheric asymmetry and @entity1 collateralization was observed. In addition, the CR, rather than CSO, was found to have topographic significance.

title: Correlation between the flow pattern of the circle of Willis and segmental perfusion asymmetry after XXXX revascularization.

answer: @entity2


abstract: This trial was designed to determine the 1-year survival rate, efficacy, and safety, produced by @entity14 and @entity1 as first line chemotherapy in @entity11 ( @entity11 ). Fifty-three @entity0 were enrolled; 51 received treatment. @entity14 1 mg/m(2), days 1-5 and @entity1 1 g/m(2) days 1 and 15 were administered IV, each drug over 30 min; cycles consisted of 28 days. Treatment continued until progressive disease or intolerable @entity2 . Nineteen @entity0 (36%) had Eastern Cooperative Oncology Group criteria performance status (ECOG PS) = 0, 34 (64%) PS = 1. Median age was 64 years; 37 @entity0 (70%) were male. HISTOLOGY: @entity7 (42%), @entity10 (28%), large cell (19%), and unclassified (11%). Among 47 evaluable @entity0 , eight (17%) had partial response, 11 (23%) had stable disease. One-year survival was 39% and median survival was 7.6 months (range, < 1-19.6). Grade 3 and 4 @entity2 included @entity13 (53%), @entity6 (18%), @entity8 (12%), @entity12 (8%), and @entity5 (8%); three @entity0 (6%) experienced @entity4 . There were no treatment-related @entity3 . The combination @entity14 / @entity1 produced a 1-year survival similar to previous @entity9 -based regimens, when used as first line chemotherapy for @entity11 . The @entity2 profile was acceptable.

title: A phase II multicenter study of combined @entity14 and @entity1 as first line chemotherapy for XXXX .

answer: @entity11


abstract: This trial was designed to determine the 1-year survival rate, efficacy, and safety, produced by @entity14 and @entity1 as first line chemotherapy in @entity11 ( @entity11 ). Fifty-three @entity0 were enrolled; 51 received treatment. @entity14 1 mg/m(2), days 1-5 and @entity1 1 g/m(2) days 1 and 15 were administered IV, each drug over 30 min; cycles consisted of 28 days. Treatment continued until progressive disease or intolerable @entity2 . Nineteen @entity0 (36%) had Eastern Cooperative Oncology Group criteria performance status (ECOG PS) = 0, 34 (64%) PS = 1. Median age was 64 years; 37 @entity0 (70%) were male. HISTOLOGY: @entity7 (42%), @entity10 (28%), large cell (19%), and unclassified (11%). Among 47 evaluable @entity0 , eight (17%) had partial response, 11 (23%) had stable disease. One-year survival was 39% and median survival was 7.6 months (range, < 1-19.6). Grade 3 and 4 @entity2 included @entity13 (53%), @entity6 (18%), @entity8 (12%), @entity12 (8%), and @entity5 (8%); three @entity0 (6%) experienced @entity4 . There were no treatment-related @entity3 . The combination @entity14 / @entity1 produced a 1-year survival similar to previous @entity9 -based regimens, when used as first line chemotherapy for @entity11 . The @entity2 profile was acceptable.

title: A phase II multicenter study of combined XXXX and @entity1 as first line chemotherapy for @entity11 .

answer: @entity14


abstract: This trial was designed to determine the 1-year survival rate, efficacy, and safety, produced by @entity14 and @entity1 as first line chemotherapy in @entity11 ( @entity11 ). Fifty-three @entity0 were enrolled; 51 received treatment. @entity14 1 mg/m(2), days 1-5 and @entity1 1 g/m(2) days 1 and 15 were administered IV, each drug over 30 min; cycles consisted of 28 days. Treatment continued until progressive disease or intolerable @entity2 . Nineteen @entity0 (36%) had Eastern Cooperative Oncology Group criteria performance status (ECOG PS) = 0, 34 (64%) PS = 1. Median age was 64 years; 37 @entity0 (70%) were male. HISTOLOGY: @entity7 (42%), @entity10 (28%), large cell (19%), and unclassified (11%). Among 47 evaluable @entity0 , eight (17%) had partial response, 11 (23%) had stable disease. One-year survival was 39% and median survival was 7.6 months (range, < 1-19.6). Grade 3 and 4 @entity2 included @entity13 (53%), @entity6 (18%), @entity8 (12%), @entity12 (8%), and @entity5 (8%); three @entity0 (6%) experienced @entity4 . There were no treatment-related @entity3 . The combination @entity14 / @entity1 produced a 1-year survival similar to previous @entity9 -based regimens, when used as first line chemotherapy for @entity11 . The @entity2 profile was acceptable.

title: A phase II multicenter study of combined @entity14 and XXXX as first line chemotherapy for @entity11 .

answer: @entity1


abstract: @entity5 administered in a doublet with @entity3 has become a standard treatment in @entity0 with advanced @entity4 ( @entity4 ). However, @entity9 appears to provide comparable efficacy with a better nonhematologic safety profile than @entity3 . Herein we report the results of a phase I/II trial of weekly @entity5 and divided-dose @entity9 in @entity0 with stage IIIB/IV @entity4 , Eastern Cooperative Oncology Group performance status < or = 2, and adequate bone marrow. @entity0 received @entity5 starting at 20 mg/m(2) (to 25 mg/m(2)) and @entity9 area under the curve (AUC) 2.5 in divided-doses, both given on Days 1 and 8 every 21-day cycle for up to 6 cycles or until disease progression. Dose-limiting @entity2 was defined for Cycles 1 and 2. @entity1 response and @entity2 were assessed using standard criteria. Twenty-one @entity0 with a mean age of 67 years (range, 43-79) and stage IIIB/IV (8/13) disease were enrolled. All but 1 @entity0 were chemotherapy-nai;ve; the majority (n = 20) had good performance status (< or = 1). Seventy-nine courses (median, 4) were administered. The @entity5 / @entity9 doublet was well tolerated, with 7 courses interrupted or delayed because of @entity2 . @entity2 were generally mild and evenly divided between hematologic (i.e., @entity6 ) and nonhematologic (i.e., fatigue). No growth factor support was required for hematologic @entity2 . There was only one case of grade 2 @entity7 , and no cases of > or = grade 2 @entity8 . There were 5 (24%) partial responses, and 9 (43%) @entity0 had stable disease. Weekly @entity5 25 mg/m(2) and divided-dose @entity9 AUC 2.5 is a well tolerated regimen with activity in advanced @entity4 @entity0 . Further evaluation of this regimen in combination with novel targeted biologic therapy is warranted.

title: Phase I/II trial of @entity5 and divided-dose @entity9 in advanced XXXX .

answer: @entity4


abstract: @entity5 administered in a doublet with @entity3 has become a standard treatment in @entity0 with advanced @entity4 ( @entity4 ). However, @entity9 appears to provide comparable efficacy with a better nonhematologic safety profile than @entity3 . Herein we report the results of a phase I/II trial of weekly @entity5 and divided-dose @entity9 in @entity0 with stage IIIB/IV @entity4 , Eastern Cooperative Oncology Group performance status < or = 2, and adequate bone marrow. @entity0 received @entity5 starting at 20 mg/m(2) (to 25 mg/m(2)) and @entity9 area under the curve (AUC) 2.5 in divided-doses, both given on Days 1 and 8 every 21-day cycle for up to 6 cycles or until disease progression. Dose-limiting @entity2 was defined for Cycles 1 and 2. @entity1 response and @entity2 were assessed using standard criteria. Twenty-one @entity0 with a mean age of 67 years (range, 43-79) and stage IIIB/IV (8/13) disease were enrolled. All but 1 @entity0 were chemotherapy-nai;ve; the majority (n = 20) had good performance status (< or = 1). Seventy-nine courses (median, 4) were administered. The @entity5 / @entity9 doublet was well tolerated, with 7 courses interrupted or delayed because of @entity2 . @entity2 were generally mild and evenly divided between hematologic (i.e., @entity6 ) and nonhematologic (i.e., fatigue). No growth factor support was required for hematologic @entity2 . There was only one case of grade 2 @entity7 , and no cases of > or = grade 2 @entity8 . There were 5 (24%) partial responses, and 9 (43%) @entity0 had stable disease. Weekly @entity5 25 mg/m(2) and divided-dose @entity9 AUC 2.5 is a well tolerated regimen with activity in advanced @entity4 @entity0 . Further evaluation of this regimen in combination with novel targeted biologic therapy is warranted.

title: Phase I/II trial of @entity5 and divided-dose XXXX in advanced @entity4 .

answer: @entity9


abstract: @entity5 administered in a doublet with @entity3 has become a standard treatment in @entity0 with advanced @entity4 ( @entity4 ). However, @entity9 appears to provide comparable efficacy with a better nonhematologic safety profile than @entity3 . Herein we report the results of a phase I/II trial of weekly @entity5 and divided-dose @entity9 in @entity0 with stage IIIB/IV @entity4 , Eastern Cooperative Oncology Group performance status < or = 2, and adequate bone marrow. @entity0 received @entity5 starting at 20 mg/m(2) (to 25 mg/m(2)) and @entity9 area under the curve (AUC) 2.5 in divided-doses, both given on Days 1 and 8 every 21-day cycle for up to 6 cycles or until disease progression. Dose-limiting @entity2 was defined for Cycles 1 and 2. @entity1 response and @entity2 were assessed using standard criteria. Twenty-one @entity0 with a mean age of 67 years (range, 43-79) and stage IIIB/IV (8/13) disease were enrolled. All but 1 @entity0 were chemotherapy-nai;ve; the majority (n = 20) had good performance status (< or = 1). Seventy-nine courses (median, 4) were administered. The @entity5 / @entity9 doublet was well tolerated, with 7 courses interrupted or delayed because of @entity2 . @entity2 were generally mild and evenly divided between hematologic (i.e., @entity6 ) and nonhematologic (i.e., fatigue). No growth factor support was required for hematologic @entity2 . There was only one case of grade 2 @entity7 , and no cases of > or = grade 2 @entity8 . There were 5 (24%) partial responses, and 9 (43%) @entity0 had stable disease. Weekly @entity5 25 mg/m(2) and divided-dose @entity9 AUC 2.5 is a well tolerated regimen with activity in advanced @entity4 @entity0 . Further evaluation of this regimen in combination with novel targeted biologic therapy is warranted.

title: Phase I/II trial of XXXX and divided-dose @entity9 in advanced @entity4 .

answer: @entity5


abstract: PURPOSE: @entity8 ( @entity8 ) inhibitors mediate a systemic antitumor activity via antiangiogenesis and seem to enhance the response of @entity2 to radiation. Radiosensitizing effects of @entity8 inhibition have not been reported for bone @entity1 . Therefore, the aim of this study was the investigation of the radiosensitizing effects of the selective @entity8 inhibitor @entity9 in secondary @entity7 of a @entity6 in vivo. MATERIALS AND METHODS: @entity0 A549 lung @entity4 were implanted into a cranial window preparation in male @entity5 @entity3 (n = 24). Animals were treated with either @entity9 or radiation (7 Gy single photon dose) alone or a combination of @entity9 and radiation, respectively. Untreated animals served as controls. The impact of radiation and @entity8 inhibition on angiogenesis, microcirculation, and @entity2 growth was analyzed over 28 days by means of intravital microscopy and histological methods. RESULTS: Monotherapies with radiation as well as @entity9 had significant antitumor effects compared to untreated controls. Both therapies reduced @entity2 growth and vascularization to a similar extent. The simultaneous administration of @entity9 and radiation further enhanced the antitumor and antiangiogenic effects of single-beam radiation. With the combined treatment approach, @entity2 vascularization and @entity2 size were decreased by 57% and 51%, respectively, as compared to monotherapy with radiation. CONCLUSION: The combined application of radiation therapy and @entity8 inhibition showed synergistic effects concerning the inhibition of @entity2 growth and @entity2 angiogenesis. Therefore, the combination of radiation with @entity8 inhibitor therapy represents a promising approach to improve the therapeutic efficacy of radiotherapy of bone @entity1 .

title: XXXX enhances radiation response of secondary @entity7 of a @entity0 @entity6 via antiangiogenesis in vivo.

answer: @entity9


abstract: PURPOSE: @entity8 ( @entity8 ) inhibitors mediate a systemic antitumor activity via antiangiogenesis and seem to enhance the response of @entity2 to radiation. Radiosensitizing effects of @entity8 inhibition have not been reported for bone @entity1 . Therefore, the aim of this study was the investigation of the radiosensitizing effects of the selective @entity8 inhibitor @entity9 in secondary @entity7 of a @entity6 in vivo. MATERIALS AND METHODS: @entity0 A549 lung @entity4 were implanted into a cranial window preparation in male @entity5 @entity3 (n = 24). Animals were treated with either @entity9 or radiation (7 Gy single photon dose) alone or a combination of @entity9 and radiation, respectively. Untreated animals served as controls. The impact of radiation and @entity8 inhibition on angiogenesis, microcirculation, and @entity2 growth was analyzed over 28 days by means of intravital microscopy and histological methods. RESULTS: Monotherapies with radiation as well as @entity9 had significant antitumor effects compared to untreated controls. Both therapies reduced @entity2 growth and vascularization to a similar extent. The simultaneous administration of @entity9 and radiation further enhanced the antitumor and antiangiogenic effects of single-beam radiation. With the combined treatment approach, @entity2 vascularization and @entity2 size were decreased by 57% and 51%, respectively, as compared to monotherapy with radiation. CONCLUSION: The combined application of radiation therapy and @entity8 inhibition showed synergistic effects concerning the inhibition of @entity2 growth and @entity2 angiogenesis. Therefore, the combination of radiation with @entity8 inhibitor therapy represents a promising approach to improve the therapeutic efficacy of radiotherapy of bone @entity1 .

title: @entity9 enhances radiation response of secondary @entity7 of a @entity0 XXXX via antiangiogenesis in vivo.

answer: @entity6


abstract: PURPOSE: @entity8 ( @entity8 ) inhibitors mediate a systemic antitumor activity via antiangiogenesis and seem to enhance the response of @entity2 to radiation. Radiosensitizing effects of @entity8 inhibition have not been reported for bone @entity1 . Therefore, the aim of this study was the investigation of the radiosensitizing effects of the selective @entity8 inhibitor @entity9 in secondary @entity7 of a @entity6 in vivo. MATERIALS AND METHODS: @entity0 A549 lung @entity4 were implanted into a cranial window preparation in male @entity5 @entity3 (n = 24). Animals were treated with either @entity9 or radiation (7 Gy single photon dose) alone or a combination of @entity9 and radiation, respectively. Untreated animals served as controls. The impact of radiation and @entity8 inhibition on angiogenesis, microcirculation, and @entity2 growth was analyzed over 28 days by means of intravital microscopy and histological methods. RESULTS: Monotherapies with radiation as well as @entity9 had significant antitumor effects compared to untreated controls. Both therapies reduced @entity2 growth and vascularization to a similar extent. The simultaneous administration of @entity9 and radiation further enhanced the antitumor and antiangiogenic effects of single-beam radiation. With the combined treatment approach, @entity2 vascularization and @entity2 size were decreased by 57% and 51%, respectively, as compared to monotherapy with radiation. CONCLUSION: The combined application of radiation therapy and @entity8 inhibition showed synergistic effects concerning the inhibition of @entity2 growth and @entity2 angiogenesis. Therefore, the combination of radiation with @entity8 inhibitor therapy represents a promising approach to improve the therapeutic efficacy of radiotherapy of bone @entity1 .

title: @entity9 enhances radiation response of secondary XXXX of a @entity0 @entity6 via antiangiogenesis in vivo.

answer: @entity7


abstract: PURPOSE: @entity8 ( @entity8 ) inhibitors mediate a systemic antitumor activity via antiangiogenesis and seem to enhance the response of @entity2 to radiation. Radiosensitizing effects of @entity8 inhibition have not been reported for bone @entity1 . Therefore, the aim of this study was the investigation of the radiosensitizing effects of the selective @entity8 inhibitor @entity9 in secondary @entity7 of a @entity6 in vivo. MATERIALS AND METHODS: @entity0 A549 lung @entity4 were implanted into a cranial window preparation in male @entity5 @entity3 (n = 24). Animals were treated with either @entity9 or radiation (7 Gy single photon dose) alone or a combination of @entity9 and radiation, respectively. Untreated animals served as controls. The impact of radiation and @entity8 inhibition on angiogenesis, microcirculation, and @entity2 growth was analyzed over 28 days by means of intravital microscopy and histological methods. RESULTS: Monotherapies with radiation as well as @entity9 had significant antitumor effects compared to untreated controls. Both therapies reduced @entity2 growth and vascularization to a similar extent. The simultaneous administration of @entity9 and radiation further enhanced the antitumor and antiangiogenic effects of single-beam radiation. With the combined treatment approach, @entity2 vascularization and @entity2 size were decreased by 57% and 51%, respectively, as compared to monotherapy with radiation. CONCLUSION: The combined application of radiation therapy and @entity8 inhibition showed synergistic effects concerning the inhibition of @entity2 growth and @entity2 angiogenesis. Therefore, the combination of radiation with @entity8 inhibitor therapy represents a promising approach to improve the therapeutic efficacy of radiotherapy of bone @entity1 .

title: @entity9 enhances radiation response of secondary @entity7 of a XXXX @entity6 via antiangiogenesis in vivo.

answer: @entity0


abstract: PURPOSE: Perineal @entity2 is a challenging complication after abdominoperineal excision (APE) of the rectum. Surgical repair can be accomplished using challenging abdominal or transperineal approaches. A laparoscopic repair using a Proceed mesh might be an easy and effective alternative. METHODS: We describe a multi-center case-series of twelve @entity0 with a symptomatic @entity1 treated by laparoscopic mesh repair. A cone-shaped 10  *  15  cm Proceed Mesh was tacked to the promontory or sacrum and sutured to the pelvic sidewalls and the anterior peritoneum. RESULTS: Twelve @entity0 underwent laparoscopic repair of their @entity1 . Four @entity0 and eight @entity0 presented with a symptomatic @entity1 after abdominoperineal excision between 2008 and 2013 and underwent a laparoscopic repair with a Proceed mesh. The median age at presentation was 53  years (range 39-68  years). The mean total theater time was 119  min (range 75-200  min). No conversion to an open procedure was needed. No early complications where seen. The mean hospital stay was 2.25  days (range 1-4  days). Three @entity0 showed recurrence, of whom two had a defect in the middle of the proceed mesh, one had a defect anterior to the previous @entity1 . All 3 @entity0 underwent a redo-laparoscopic repair with mesh. CONCLUSION: In this case series we present an alternative approach for the surgical repair of perineal @entity2 . Based on our experience, @entity1 after APE can be repaired safely and effectively using the described laparoscopic technique.

title: Laparoscopic repair of XXXX after abdominoperineal excision.

answer: @entity1


abstract: The gene VI protein (P6) of @entity2 ) functions as a virulence factor in crucifers by eliciting @entity1 in infected plants. The ability to induce @entity4 has been associated previously with P6 through gene-swapping experiments between strains and through the development of transgenic plants that express P6. The primary role that has been identified for P6 in the @entity2 infection cycle is to modify the host translation machinery to facilitate the translation of the polycistronic @entity2 35S RNA. This function for P6 has been designated as the translational transactivator ( @entity3 ) function. In the present study, we have characterized an unusual variant of P6, derived from @entity2 D4, that does not induce @entity4 upon transformation into @entity0 . The level of D4 P6 produced in transgenic @entity0 line D4-2 was comparable to the amount found in transgenic plants homozygous for W260 and CM1841 P6, two versions of P6 that induce strong @entity1 and stunting in @entity0 . A complementation assay proved that P6 expressed in the D4-2 line was functional, as it could support the systemic infection of a CM1841 mutant that contained a lethal frame-shift mutation within gene VI. This complementation assay allowed us to separately assess the contribution of CM1841 gene VI to symptom development versus the contribution of other CM1841 genes. Furthermore, a previous study had shown that the @entity3 activity of D4 P6 was comparable to that of W260 P6. That comparative analysis of @entity3 function, coupled with the characterization of the D4-2 transgenic line in the present paper, indicates that the @entity3 function of P6 may play only a minor role in the development of @entity1 .

title: Differential induction of symptoms in @entity0 by P6 of XXXX .

answer: @entity2


abstract: The gene VI protein (P6) of @entity2 ) functions as a virulence factor in crucifers by eliciting @entity1 in infected plants. The ability to induce @entity4 has been associated previously with P6 through gene-swapping experiments between strains and through the development of transgenic plants that express P6. The primary role that has been identified for P6 in the @entity2 infection cycle is to modify the host translation machinery to facilitate the translation of the polycistronic @entity2 35S RNA. This function for P6 has been designated as the translational transactivator ( @entity3 ) function. In the present study, we have characterized an unusual variant of P6, derived from @entity2 D4, that does not induce @entity4 upon transformation into @entity0 . The level of D4 P6 produced in transgenic @entity0 line D4-2 was comparable to the amount found in transgenic plants homozygous for W260 and CM1841 P6, two versions of P6 that induce strong @entity1 and stunting in @entity0 . A complementation assay proved that P6 expressed in the D4-2 line was functional, as it could support the systemic infection of a CM1841 mutant that contained a lethal frame-shift mutation within gene VI. This complementation assay allowed us to separately assess the contribution of CM1841 gene VI to symptom development versus the contribution of other CM1841 genes. Furthermore, a previous study had shown that the @entity3 activity of D4 P6 was comparable to that of W260 P6. That comparative analysis of @entity3 function, coupled with the characterization of the D4-2 transgenic line in the present paper, indicates that the @entity3 function of P6 may play only a minor role in the development of @entity1 .

title: Differential induction of symptoms in XXXX by P6 of @entity2 .

answer: @entity0


abstract: BACKGROUND: Transradial approach (TRA), when compared with transfemoral, improves the safety of percutaneous coronary procedures. @entity1 variants are known to hinder the performance of transradial approach percutaneous coronary procedures. Data on the occurrence of @entity1 variants in the right and left arm arterial axes of individual @entity0 are lacking. METHODS AND RESULTS: From a single-center prospective registry, we selected all @entity0 in whom bilateral upper limb arterial anatomy was assessed based on the performance of left and right radial catheterization obtained during the same or during repeat coronary diagnostic or interventional procedure(s). The occurrence of upper right and left limb @entity1 variants was classified according to the previously described operative ABC classification. A total of 610 @entity0 were identified. An ABC upper limb @entity1 variant was detected in 156 (25.6%) @entity0 . Variants were right-sided only in 65 (11.0%), left-sided only in 40 (6.6%), and bilateral in 46 (7.5%) @entity0 . Thus, @entity1 variants were significantly more common in the right side (P=0.02). Bilateral arterial variants were significantly associated with age, female sex, and valvulopathy. Both A (radial/brachial) and B (axillary/subclavian/innominate) variants exhibited concordance across the 2 sides (odds ratio, 7.2; 95% confidence interval, 4.1-12.7 and 8.0; 95% confidence interval, 2.1-30.9, respectively). CONCLUSIONS: The occurrence of an anatomic variant potentially hindering transradial approach coronary diagnostic or interventional procedures is bilateral in <8% of cases and is more common in the right arm. Such information may guide, during the clinical practice, the access selection in the case of repeat procedures or need for additional accesses.

title: Comparison of Right and Left Upper Limb Arterial Variants in XXXX Undergoing Bilateral Transradial Procedures.

answer: @entity0


abstract: The objective of this study was to estimate the overall prevalence of animals that were infected with @entity3 ssp. @entity2 in a subpopulation of Alabama beef @entity1 . This was determined using a commercial enzyme-linked immunosorbent assay (ELISA) for the detection of @entity3 ssp. @entity2 -specific antibodies in serum. Serum was collected from 79 herds that were participating in the Alabama Brucellosis Certification program. A total of 2,073 beef @entity1 were randomly tested by selecting 30 animals per herd in herds greater than 30 and selecting all animals in herds 30 and less for testing. It has been estimated that the commercial ELISA test used has a 60% sensitivity and a 97% specificity. Of the 79 herds tested, 29 herds were seronegative, 24 herds had 1-2 positive animals, and 26 herds had 3 or more seropositive animals. The average number of infected animals per positive herd was 3.3. In addition, a calculated minimum of 53.5% of the herds were identified as Johne's positive herds with a 95% confidence level. Of the total number of animals tested, 8.0% (166/2,073) of them were positive by the ELISA. After adjustments for test sensitivity and specificity and the proportion of animals sampled per herd, the true prevalence was calculated to be 8.75%. These data suggest that approximately 50% of the herds are infected with @entity3 ssp. @entity2 , and the overall prevalence of @entity0 in Alabama beef @entity1 is approximately 8%, which correlates with other previously published regional estimates.

title: An estimated prevalence of XXXX in a subpopulation of Alabama beef @entity1 .

answer: @entity2


abstract: The objective of this study was to estimate the overall prevalence of animals that were infected with @entity3 ssp. @entity2 in a subpopulation of Alabama beef @entity1 . This was determined using a commercial enzyme-linked immunosorbent assay (ELISA) for the detection of @entity3 ssp. @entity2 -specific antibodies in serum. Serum was collected from 79 herds that were participating in the Alabama Brucellosis Certification program. A total of 2,073 beef @entity1 were randomly tested by selecting 30 animals per herd in herds greater than 30 and selecting all animals in herds 30 and less for testing. It has been estimated that the commercial ELISA test used has a 60% sensitivity and a 97% specificity. Of the 79 herds tested, 29 herds were seronegative, 24 herds had 1-2 positive animals, and 26 herds had 3 or more seropositive animals. The average number of infected animals per positive herd was 3.3. In addition, a calculated minimum of 53.5% of the herds were identified as Johne's positive herds with a 95% confidence level. Of the total number of animals tested, 8.0% (166/2,073) of them were positive by the ELISA. After adjustments for test sensitivity and specificity and the proportion of animals sampled per herd, the true prevalence was calculated to be 8.75%. These data suggest that approximately 50% of the herds are infected with @entity3 ssp. @entity2 , and the overall prevalence of @entity0 in Alabama beef @entity1 is approximately 8%, which correlates with other previously published regional estimates.

title: An estimated prevalence of @entity2 in a subpopulation of Alabama beef XXXX .

answer: @entity1


abstract: BACKGROUND AND STUDY AIMS: This multicenter, prospective, country-wide quality-assurance study at more than 300 hospitals in Germany was designed to characterize and analyze the diagnostic accuracy of rectal endoscopic ultrasound (EUS) in the routine clinical staging of @entity2 (depth of @entity1 infiltration). @entity0 AND METHODS: @entity0 were surveyed between 1 January 2000 and 31 December 2008. Those who received neoadjuvant therapy after EUS were excluded. The correspondence between the EUS assessment of @entity1 depth (uT) and that determined by histology (pT) was calculated, and the influence of hospital volume upon the sensitivity, specificity, and positive and negative predictive values was investigated. RESULTS: At 384 hospitals providing care at all levels, 29206 @entity0 were included; of the 27458 treated by surgical resection, EUS was performed for 12235 (44.6%). Of these, 7096 did not receive neoadjuvant radiochemotherapy, allowing a uT-pT comparison. The uT-pT correspondence was 64.7% (95% confidence interval [CI] 63.6%-65.8%); the frequency of understaging was 18% (95%CI 17.1%-18.9%) and that of overstaging was 17.3% (95%CI 16.4%-18.2%). The kappa coefficient was greatest in the category T1 (k   =   0.591). For T3 @entity1 k was 0.468. The poorest correspondence was found for T2 and T4 @entity1 (k   =   0.367 and 0.321, respectively). A breakdown by hospital volume showed that the uT-pT correspondence was 63.2% (95%CI 61.5%-64.9%) for hospitals undertaking  <=   10   EUS/year, 64.6% (95%CI 62.9%-66.2%) for doing 11-30   EUS/year, and 73.1% (95%CI 69.4%-76.5%) for those hospitals performing >   30   EUS/year. CONCLUSIONS: In clinical routine, the diagnostic accuracy of transrectal ultrasound in staging @entity2 does not attain the very good results reported in the literature. Only in the hands of diagnosticians with a large case volume of @entity2 @entity0 can EUS lead to therapy-relevant decisions.

title: Endorectal ultrasound in XXXX --do the literature results really correspond to the realities of routine clinical care?

answer: @entity2


abstract: 148 @entity0 under the age of 5 have been identified from the files of the National Cancer Registry of the GDR. They all had @entity1 of the central nervous system (CNS), which were histopathologically diagnosed in the period 1975 to 1980. Additional information concerning their health status and diseases was collected from birth history, postnatal care-unit files, out- and in- @entity0 medical records and other sources. Based on these materials the time of clinical onset of the disease has been elucidated. In 12 of the 148 @entity0 the onset was in the perinatal period and in another 36 during the first year of life. 1,322,450 births took place in the GDR in the index period. The incidence of @entity1 of the CNS with onset of signs and symptoms prior to the end of the first year of life was 3.6 per 100,000 births. The most common type of @entity1 was @entity3 , with an incidence of 0.9/100,000. It is followed in frequency by other @entity6 and by intracranial @entity2 . No @entity5 or @entity4 had their onset in infancy. The conclusion is drawn that the incidence of @entity6 is almost the same in newborns and @entity0 as it is in older age groups. The findings contradict the genera view, that CNS @entity1 in @entity0 are very rare.

title: [Epidemiology of XXXX of the central nervous system in the 1st year of life].

answer: @entity1


abstract: BACKGROUND: There is abundant evidence that glucotoxicity and lipotoxicity contribute to impaired b-cell function in @entity1 2 @entity0 . Interestingly, @entity4 (AA) derangement is also a characteristic part of the @entity0 state. The acute effects of AA on pancreatic b-cell function have been widely explored; however, to our knowledge, the chronic effects of AA, e.g. @entity6 (Pro), @entity5 ( @entity7 ), and @entity3 (Leu), on pancreatic b-cell function and integrity have not yet been studied. We aimed to investigate global alterations in b-cell gene expression after long-term exposure of clonal INS-1E cells to elevated level of specific AA in vitro. METHODS: Global gene expression profiling was performed to characterize genes differently modified by Pro, @entity7 , and Leu, respectively, in INS-1E cells. RESULTS: Gene expression profiling revealed significant changes in INS-1E cell mRNAs involved in the control of several aspects of b-cell function, e.g. epigenetic regulation of gene expression, metabolism, innate and adaptive immune responses, cellular signalling, protein synthesis, apoptosis, and cellular stress response. After 72 h, INS-1E cells were differentially regulated (>= 1.5- or  <= -1.5-fold) by Pro (295 transcripts), @entity7 (301 transcripts), and Leu (701 transcripts). It appears that @entity7 effects changes opposite to those induced by Leu and/or Pro. CONCLUSIONS: AA appears to participate in and to influence many physiological processes including those involved in @entity2 metabolism, immune responses, and oxidative phosphorylation. Whether such events promote the b-cell dysfunction and the b-cell failure in @entity0 remains to be elucidated. Our data strongly indicate that AA elevation may take part in the progressive development of @entity1 2 @entity0 .

title: XXXX -induced gene expression profiling in clonal b-cell line INS-1E cells.

answer: @entity4


abstract: BACKGROUND: Epidermal pseudotumours from Hippoglossoides dubius and Acanthogobius flavimanus in Japan and gill lesions in Limanda limanda from the UK have been shown to be caused by phylogenetically related protozoan parasites, known collectively as X-cells. However, the phylogenetic position of the X-cell group is not well supported within any of the existing protozoan phyla and they are currently thought to be members of the Alveolata.Ultrastructural features of X-cells in fish pseudotumours are somewhat limited and no typical environmental stages, such as spores or flagellated cells, have been observed. The life cycles for these parasites have not been demonstrated and it remains unknown how transmission to a new host occurs. In the present study, pseudobranchial pseudotumours from @entity1 , @entity1 , in Iceland and @entity0 from the northern black flounder, Pseudopleuronectes obscurus, in Japan were used in experimental transmission studies to establish whether direct transmission of the parasite is achievable. In addition, X-cells from @entity1 were sequenced to confirm whether they are phylogenetically related to other X-cells and @entity0 from the northern black flounder were analysed to establish whether the same parasite is responsible for infecting different flatfish species in Japan. RESULTS: Phylogenetic analyses of small subunit ribosomal DNA (SSU rDNA) sequence data from @entity1 X-cells show that they are a related parasite that occupies a basal position to the clade containing other X-cell parasites. The X-cell parasite causing @entity0 in @entity2 is the same parasite that causes pseudotumours in @entity3 . Direct, fish to fish, transmission of the X-cell parasites used in this study, via oral feeding or injection, was not achieved. Non-amoeboid X-cells are contained within discrete sac-like structures that are loosely attached to @entity0 in flatfish; these X-cells are able to tolerate exposure to seawater. A sensitive nested PCR assay was developed for the sub clinical detection of both parasites and to assist in future life cycle studies. PCR revealed that the parasite in @entity2 was detectable in non-pseudotumourous areas of fish that had pseudotumours present in other areas of the body. CONCLUSIONS: The inability to successfully transmit both parasites in this study suggests that either host detachment combined with a period of independent development or an alternate host is required to complete the life cycle for X-cell parasites. Phylogenetic analyses of SSU rDNA confirm a monophyletic grouping for all sequenced X-cell parasites, but do not robustly support their placement within any established protist phylum. Analysis of SSU rDNA from X-cells in Japanese flatfish reveals that the same parasite can infect more than one species of fish.

title: Molecular identification and transmission studies of X-cell parasites from XXXX @entity1 (Gadiformes: Gadidae) and the northern black flounder Pseudopleuronectes obscurus (Pleuronectiformes: Pleuronectidae).

answer: @entity1


abstract: BACKGROUND: Epidermal pseudotumours from Hippoglossoides dubius and Acanthogobius flavimanus in Japan and gill lesions in Limanda limanda from the UK have been shown to be caused by phylogenetically related protozoan parasites, known collectively as X-cells. However, the phylogenetic position of the X-cell group is not well supported within any of the existing protozoan phyla and they are currently thought to be members of the Alveolata.Ultrastructural features of X-cells in fish pseudotumours are somewhat limited and no typical environmental stages, such as spores or flagellated cells, have been observed. The life cycles for these parasites have not been demonstrated and it remains unknown how transmission to a new host occurs. In the present study, pseudobranchial pseudotumours from @entity1 , @entity1 , in Iceland and @entity0 from the northern black flounder, Pseudopleuronectes obscurus, in Japan were used in experimental transmission studies to establish whether direct transmission of the parasite is achievable. In addition, X-cells from @entity1 were sequenced to confirm whether they are phylogenetically related to other X-cells and @entity0 from the northern black flounder were analysed to establish whether the same parasite is responsible for infecting different flatfish species in Japan. RESULTS: Phylogenetic analyses of small subunit ribosomal DNA (SSU rDNA) sequence data from @entity1 X-cells show that they are a related parasite that occupies a basal position to the clade containing other X-cell parasites. The X-cell parasite causing @entity0 in @entity2 is the same parasite that causes pseudotumours in @entity3 . Direct, fish to fish, transmission of the X-cell parasites used in this study, via oral feeding or injection, was not achieved. Non-amoeboid X-cells are contained within discrete sac-like structures that are loosely attached to @entity0 in flatfish; these X-cells are able to tolerate exposure to seawater. A sensitive nested PCR assay was developed for the sub clinical detection of both parasites and to assist in future life cycle studies. PCR revealed that the parasite in @entity2 was detectable in non-pseudotumourous areas of fish that had pseudotumours present in other areas of the body. CONCLUSIONS: The inability to successfully transmit both parasites in this study suggests that either host detachment combined with a period of independent development or an alternate host is required to complete the life cycle for X-cell parasites. Phylogenetic analyses of SSU rDNA confirm a monophyletic grouping for all sequenced X-cell parasites, but do not robustly support their placement within any established protist phylum. Analysis of SSU rDNA from X-cells in Japanese flatfish reveals that the same parasite can infect more than one species of fish.

title: Molecular identification and transmission studies of X-cell parasites from @entity1 XXXX (Gadiformes: Gadidae) and the northern black flounder Pseudopleuronectes obscurus (Pleuronectiformes: Pleuronectidae).

answer: @entity1


abstract: BACKGROUND: The goal of this study was to estimate the distribution of udder pathogens and their antibiotic resistance in Estonia during the years 2007-2009. METHODS: The bacteriological findings reported in this study originate from quarter milk samples collected from @entity2 on Estonian dairy farms that had clinical or subclinical @entity7 . The samples were submitted by local veterinarians to the Estonian Veterinary and Food Laboratory during 2007-2009. Milk samples were examined by conventional bacteriology. In vitro antimicrobial susceptibility testing was performed with the disc diffusion test. Logistic regression with a random herd effect to control for clustering was used for statistical analysis. RESULTS: During the study period, 3058 clinical @entity7 samples from 190 farms and 5146 subclinical @entity7 samples from 274 farms were investigated. Positive results were found in 57% of the samples (4680 out of 8204), and the proportion did not differ according to year (p > 0.05). The proportion of bacteriologically negative samples was 22.3% and that of mixed growth was 20.6%. @entity10 . uberis) was the bacterium isolated most frequently (18.4%) from cases of clinical @entity7 , followed by @entity3 (E. coli) (15.9%) and @entity9 . agalactiae) (11.9%). The bacteria that caused subclinical @entity7 were mainly @entity4 ( @entity4 ) (20%) and coagulase-negative staphylococci (CNS) (15.4%). The probability of isolating @entity4 from milk samples was significantly higher on farms that had fewer than 30 @entity2 , when compared with farms that had more than 100 @entity2 (p < 0.005). A significantly higher risk of Str. agalactiae @entity1 was found on farms with more than 600 @entity2 (p = 0.034) compared with smaller farms. The proportion of @entity4 and CNS isolates that were resistant to @entity0 was 61.4% and 38.5%, respectively. Among the @entity3 isolates, @entity6 , @entity8 and @entity5 resistance were observed in 24.3%, 15.6% and 13.5%, respectively. CONCLUSIONS: This study showed that the main pathogens associated with clinical @entity7 were Str. uberis and @entity3 . Subclinical @entity7 was caused mainly by @entity4 and CNS. The number of @entity4 and Str. agalactiae isolates depended on herd size. Antimicrobial resistance was highly prevalent, especially @entity0 resistance in @entity4 and CNS.

title: Udder pathogens and their resistance to antimicrobial agents in dairy XXXX in Estonia.

answer: @entity2


abstract: OBJECTIVE: To evaluate the use of preoperative transcervical @entity3 for reducing @entity2 from laparoscopic sterilization with Filshie clips. DESIGN: A double blind, randomized, placebo-controlled trial. SETTING: Gynecologic day-care clinic of Vejle Hospital, Vejle, Denmark. SAMPLE: Seventy-eight healthy @entity0 were attending the public hospital requesting sterilization. METHODS: @entity0 received @entity4 0.25% 20 mL or placebo normal saline 20 mL injected into the uterus, though the fallopian tubes and into the pelvis before tubal occlusion with Filshie clips. MAIN OUTCOME MEASURES: Post-operative visual analog @entity1 score and request for @entity3 were recorded. RESULTS: At 30 min after clip application there was a non-significant reduction in @entity1 -score on VAS. However, @entity5 h median @entity1 score on VAS was similar in both groups. @entity0 request for postoperative @entity3 was similar in the two groups. CONCLUSIONS: Preoperative transcervical perfusion of the uterus, fallopian tubes and into the pelvis did not reduce @entity2 or request for analgesics after laparoscopic sterilization with Filshie clips.

title: Preoperative transcervical XXXX for laparoscopic sterilization with Filshie clips. A double blind randomized trial.

answer: @entity3